HLAVNÍ TÉMA Novinky v diagnostice a léčbě kardiomyopatií 104 | VNITŘNÍ LÉKAŘSTVÍ / Vnitř Lék. 2023;69(2):89-104 / www.casopisvnitrnilekarstvi.cz selhání. Léčba se tedy řídí platnými doporučeními ESC pro diagnostiku a léčbu akutního a chronického srdečního selhání a doporučeními pro léčbu arytmií. Vzhledem k riziku tvorby intrakardiálních trombů a následné kardioembolizaci je u nemocných s EFLK pod 40 % doporučena trvalá antikoagulační léčba (69). Závěr Problematika kardiomyopatií je velice široká a obsáhnout mož‑ nosti jejich správné diagnostiky, diferenciální diagnostiky a léčby není snadné. Současně jde o poměrně často se vyskytující one‑ mocnění, nezřídka u mladých jedinců, které – není‑li včas a správně diagnostikováno a léčeno – může být spojeno s významnou morbi‑ ditou i mortalitou. Jejich projevy mohou být v některých případech multisystémové a přesahují tak rámec kardiologie. Současně došlo v posledních letech k dramatickým změnám v dostupnosti řady moderních diagnostických metod i terapeutických postupů, které jsme se v textu pokusili shrnout. Podpořeno grantem AZV MZ ČR NU22-02-00418 LITERATURA 1. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a posi‑ tion statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29(2):270-276. doi:10.1093/eurheartj/ehm342 2. Arbustini E, Narula N, Tavazzi L, et al. The MOGE(S) classification of cardiomyopathy for clinicians. J Am Coll Cardiol. 2014;64(3):304-318. doi:10.1016/j.jacc.2014. 05. 027 3. Merlo M, Gagno G, Baritussio A, et al. Clinical application of CMR in cardiomyopathies: evolving concepts and techniques : A position paper of myocardial and pericardial di‑ seases and cardiac magnetic resonance working groups of Italian society of cardiology. Heart Fail Rev. 2023;28(1):77-95. doi:10.1007/s10741-022-10235-9 4. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and tre‑ atment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. doi:10.1093/ eurheartj/ehab368 5. Arbustini E, Behr ER, Carrier L, et al. Interpretation and actionability of genetic vari‑ ants in cardiomyopathies: a position statement from the European Society of Cardiolo‑ gy Council on cardiovascular genomics. Eur Heart J. 2022;43(20):1901-1916. doi:10.1093/ eurheartj/ehab895 6. Ammirati E, Buono A, Moroni F, et al. State‑of‑the‑Art of Endomyocardial Biopsy on Acute Myocarditis and Chronic Inflammatory Cardiomyopathy. Curr Cardiol Rep. 2022;24(5):597609. doi:10.1007/s11886-022-01680-x 7. Seferović PM, Tsutsui H, McNamara DM, et al. Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on en‑ domyocardial biopsy. Eur J Heart Fail. 2021;23(6):854-871. doi:10.1002/ejhf.2190 8. Caforio ALP, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, dia‑ gnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(33):2636-2648, 2648a-2648d. doi:10.1093/eurheartj/eht210 9. Veselka J, Anavekar NS, Charron P. Hypertrophic obstructive cardiomyopathy. Lancet Lond Engl. 2017;389(10075):1253-1267. doi:10.1016/S0140-6736(16)31321-6 10. Bláha M. (Athlete’s heart vs hypertrophic cardiomyopathy - differential diagnostics according to current guidelines). Cor Vasa. 2020;62(1):50-55. doi:10.33678/cor.2019.087 11. Brenes JC, Doltra A, Prat S. Cardiac magnetic resonance imaging in the evaluation of patients with hypertrophic cardiomyopathy. Glob Cardiol Sci Pract. 2018;2018(3):22. doi:10.21542/gcsp.2018.22 12. Palandri C, Santini L, Argirò A, et al. Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside. Drugs. 2022;82(8):889-912. doi:10.1007/s40265022-01728-w 13. Olivotto I, Oreziak A, Barriales‑Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER‑HCM): a randomised, double‑blind, placebo‑controlled, phase 3 trial. Lancet Lond Engl. 2020;396(10253):759-769. doi:10.1016/ S0140-6736(20)31792-X 14. Hegde SM, Lester SJ, Solomon SD, et al. Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2021;78(25):2518-2532. doi:10.1016/j.jacc.2021. 09. 1381 15. Ho CY, Mealiffe ME, Bach RG, et al. Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2020;75(21):26492660. doi:10.1016/j.jacc.2020. 03. 064 16. Sigwart U. Non‑surgical myocardial reduction for hypertrophic obstructive cardiomyo‑ pathy. The Lancet. 1995;346(8969):211-214. doi:10.1016/S0140-6736(95)91267-3 17. Bytyçi I, Nistri S, Mörner S, Henein MY. Alcohol Septal Ablation versus Septal Myectomy Treatment of Obstructive Hypertrophic Cardiomyopathy: A Systematic Review and Meta ‑Analysis. J Clin Med. 2020;9(10):3062. doi:10.3390/jcm9103062 18. Lawrenz T, Kuhn H. Endocardial radiofrequency ablation of septal hypertrophy. A new catheter‑based modality of gradient reduction in hypertrophic obstructive cardiomyo‑ pathy. Z Kardiol. 2004;93(6):493-499. doi:10.1007/s00392-004-0097-x 19. Lawrenz T, Lawin D, Radke K, Stellbrink C. Acute and chronic effects of endocardial radiofrequency ablation of septal hypertrophy in HOCM. J Cardiovasc Electrophysiol. 2021;32(10):2617-2624. doi:10.1111/jce.15203 20. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Re‑ port of the American College of Cardiology/American Heart Association Joint Commit‑ tee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020;76(25):3022-3055. doi:10.1016/j. jacc.2020. 08. 044 21. Authors/Task Force members, Elliott PM, Anastasakis A, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Socie‑ ty of Cardiology (ESC). Eur Heart J. 2014;35(39):2733-2779. doi:10.1093/eurheartj/ehu284 22. Tower‑Rader A, Jaber WA. Multimodality Imaging Assessment of Fabry Disease. Circ Cardiovasc Imaging. 2019;12(11):e009013. doi:10.1161/CIRCIMAGING.119.009013 23. Pieroni M, Moon JC, Arbustini E, et al. Cardiac Involvement in Fabry Disease: JACC Re‑ view Topic of the Week. J Am Coll Cardiol. 2021;77(7):922-936. doi:10.1016/j.jacc.2020. 12. 024 24. Zemánek D, Januška J, Honěk T, et al. Nationwide screening of Fabry disease in pati‑ ents with hypertrophic cardiomyopathy in Czech Republic. ESC Heart Fail. 2022;9(6):41604166. doi:10.1002/ehf2.14135 25. Weidemann F, Jovanovic A, Herrmann K, Vardarli I. Chaperone Therapy in Fabry Disea‑ se. Int J Mol Sci. 2022;23(3):1887. doi:10.3390/ijms23031887 26. El Dib R, Gomaa H, Carvalho RP, et al. Enzyme replacement therapy for Anderson ‑Fabry disease. Cochrane Database Syst Rev. 2016;7(7):CD006663. doi:10.1002/14651858. CD006663.pub4 27. Simonetta I, Tuttolomondo A, Daidone M, Miceli S, Pinto A. Treatment of Anderson‑Fabry Disease. Curr Pharm Des. 2020;26(40):5089-5099. doi:10.2174/1381612826666200317142412 28. Pinto YM, Elliott PM, Arbustini E, et al. Proposal for a revised definition of dilated car‑ diomyopathy, hypokinetic non‑dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2016;37(23):1850-1858. doi:10.1093/eurheartj/ehv727 29. Diagnosis and Management of Rare Cardiomyopathies in Adult and Paediatric Pati‑ ents. A Position Paper of the Italian Society of Cardiology (SIC) and Italian Society of Pa‑ ediatric Cardiology (SICP) | Elsevier Enhanced Reader. doi:10.1016/j.ijcard.2022. 03. 050 30. Schultheiss HP, Fairweather D, Caforio ALP, et al. Dilated cardiomyopathy. Nat Rev Dis Primer. 2019;5(1):32. doi:10.1038/s41572-019-0084-1 31. Towbin JA, McKenna WJ, Abrams DJ, et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. He‑ art Rhythm. 2019;16(11):e301-e372. doi:10.1016/j.hrthm.2019. 05. 007 32. Wilde AAM, Semsarian C, Márquez MF, et al. European Heart Rhythm Association (EHRA)/ Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American He‑ art Rhythm Society (LAHRS) Expert Consensus Statement on the State of Genetic Testing for Cardiac Diseases. Heart Rhythm. 2022;19(7):e1-e60. doi:10.1016/j.hrthm.2022. 03. 1225 33. Donal E, Delgado V, Bucciarelli‑Ducci C, et al. Multimodality imaging in the diagnosis, risk stratification, and management of patients with dilated cardiomyopathies: an expert consensus document from the European Association of Cardiovascular Imaging. Eur He‑ art J Cardiovasc Imaging. 2019;20(10):1075-1093. doi:10.1093/ehjci/jez178 34. Di Marco A, Anguera I, Schmitt M, et al. Late Gadolinium Enhancement and the Risk for Ventricular Arrhythmias or Sudden Death in Dilated Cardiomyopathy: Systematic Re‑ view and Meta‑Analysis. JACC Heart Fail. 2017;5(1):28-38. doi:10.1016/j.jchf.2016. 09. 017 35. Li S, Zhou D, Sirajuddin A, et al. T1 Mapping and Extracellular Volume Fraction in Di‑ lated Cardiomyopathy: A Prognosis Study. JACC Cardiovasc Imaging. 2022;15(4):578-590. doi:10.1016/j.jcmg.2021. 07. 023 36. Halliday BP. State of the art: multimodality imaging in dilated cardiomyopathy. Heart Br Card Soc. 2022;108(23):1910-1917. doi:10.1136/heartjnl-2022-321116 37. Halliday BP, Wassall R, Lota AS, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED‑HF): an open‑label, pi‑ lot, randomised trial. Lancet Lond Engl. 2019;393(10166):61-73. doi:10.1016/S0140-6736(18)‑ 32484-X Další literatura u autorů a na www.casopisvnitrnilekarstvi.cz
RkJQdWJsaXNoZXIy NDA4Mjc=